Citrullinemia, Type Ii, Neonatal-onset

Overview of Citrullinemia, Type Ii, Neonatal-onset

Most recent studies have shown that Citrullinemia, Type Ii, Neonatal-onset shares some biological mechanisms with aminoacidemia, atresia, biliary-atresia, cholestasis, citrullinemia, failure-to-thrive, fatty-liver, galactosemias, hepatitis, hyperammonemia, hypoglycemia, hypoproteinemia, icterus, inborn-errors-of-metabolism, intrahepatic-cholestasis, liver-diseases, liver-dysfunction, liver-failure, neonatal-hepatitis.

Among the many pathways, these few ones have gauged particular interests from scientists studying Citrullinemia, Type Ii, Neonatal-onset, and have been seen in publications frequently: Coagulation, Excretion, Fatty Acid Oxidation, Gluconeogenesis, Glycolysis, Pathogenesis, Transport, Urea Cycle

Quite a number of genes have been found to play important roles in Citrullinemia, Type Ii, Neonatal-onset, such as AFP, ALB, ASRGL1, ASS1, ATRNL1, CCL27, MCAT, MCPH1, NAT10, OTC, PAH, PDLIM3, SLC16A1, SLC17A5, SLC25A12, SLC25A13, SLPI, TRIM26. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.

Citrullinemia, Type Ii, Neonatal-onset Related Genes

click to see detail information for each gene

Pathways Related to Citrullinemia, Type Ii, Neonatal-onset

This information is being compiled and will come in a future update

Related Diseases